Introduction
============

Ameliorating the side effects of clinically administered drugs is an important aspect of human health, even if the side effects occur rarely. Oseltamivir (Moscona, [@b38]; De Clercq, [@b9]; Jefferson *et al*., [@b25]) exhibits potent antiviral activity against the influenza virus (Neumann *et al*., [@b40]; Medina and García-Sastre, [@b36]), a virus that has caused more than 50 million deaths throughout human history. The drug primarily inhibits neuraminidase, an enzyme essential for the release of virions from infected cells. Oseltamivir is administered as an inactive prodrug in an ethyl ester form (oseltamivir ethyl ester, OEE), which is converted *in vivo* to its active carboxylate form (oseltamivir carboxylate, OC), as shown in [Figure 1](#fig01){ref-type="fig"}A--C (Abdel-Rahman *et al*., [@b1]).

![Inhibition of MAO-A by OEE, but not by OC. (A) Chemical structure and ^1^H-NMR spectrum of the purified OEE. (B) Chemical structure and ^1^H-NMR spectrum of the purified OC. (C) Conversion from the OEE to OC. OEE and OC harbour an ethyl ester residue and a carboxylic acid residue respectively. (D) MAO-A activity in the presence of OEE or OC. The vertical axis represents product formation (as a percentage of the control). MAO assays were performed in the absence (control) or presence of OEE or OC (1, 10, 25, 50 or 100 μM); assays were performed in triplicate. A 100% value equates to a luminescence reading of 2 × 10^6^. (E) Schema of the experiment shown in (F). OEE or OC was added to the reaction either before (a) or after (b) the monoamine oxidation step. (F) Confirmation that MAO inhibition by the OEE is due to the targeting of monoamine oxidation. Panels (a) and (b) show the results of the effects on MAO by OEE or OC before or after the reaction respectively. The vertical axis represents product formation as a percentage of the control without inhibitor; assays were performed in triplicate. \**P* \< 0.05, and \*\**P* \< 0.01 (vs. the control). Data are presented as mean ± SD.](bph0169-0115-f1){#fig01}

Since 1999, about 50 million people, of whom approximately 75% are Japanese, have been treated with oseltamivir; the possible adverse effects of this drug are therefore an important issue. In rare instances reported mainly in Japan, individuals receiving oseltamivir, who were typically under the age of 20 years, showed adverse psychological and neuropsychiatrical effects (Maxwell, [@b34]; Jefferson *et al*., [@b26]; Kitching *et al*., [@b31]; Nakamura *et al*., [@b39]; L\'Huillier *et al*., [@b32]), such as dyskinaesia and depressive episodes (Chung and Joung, [@b6]; Kadowaki *et al*., [@b27]). These effects have been compiled in documents published by the US Food and Drug Administration (FDA) (<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095044.htm>, UCM134319.pdf and UCM303004.pdf: URLs of other FDA information are shown in the Supporting Information). Reports of oseltamivir-related adverse events especially increased in 2009 when an influenza pandemic occurred and large amounts of this drug were prescribed (UCM303007.pdf), suggesting a correlation. However, the link between oseltamivir and neuropsychiatric adverse effects remains controversial, as several studies have shown that oseltamivir has no endogenous targets and causes no significant abnormal behaviour in humans (Toovey *et al*., [@b53]; Lindemann *et al*., [@b33]; Donner *et al*., [@b11]). Moreover, a report published by the US FDA -- UCM303008.pdf on the FDA website -- concluded that there is no evidence for neuropsychiatric adverse effects of oseltamivir.

Studies have shown that oseltamivir crosses the blood--brain barrier in animals, including primates (Takashima *et al*., [@b51]) and rats (Ose *et al*., [@b41]; [@b42]; Hatori *et al*., [@b19]; [@b20]; Oshima *et al*., [@b43]; Takashima *et al*., [@b51]); brain uptake is greater in younger versus older animals. OEE has been reported to have multiple effects on central nervous system function *in vivo* and *in vitro*: interaction with neurostimulants to alter synaptic plasticity or behaviour (Izumi *et al*., [@b24]); neuroexcitation (Izumi *et al*., [@b23]); enhancement of hippocampal network synchronization (Usami *et al*., [@b55]); and interaction with alcohol (Izumi *et al*., [@b23]), caffeine (Uchiyama *et al*., [@b54]), and morphine (Crain and Shen, [@b8]) to affect neuronal activity. Oseltamivir also increases the level of dopamine in the rat cortex (Yoshino *et al*., [@b58]; Guzmán *et al*., [@b16]) and dopamine D2 agonist-mediated abnormal behaviour (Suzuki and Masuda, [@b50]); however, it does not alter the release or re-uptake of monoamines or GTP binding in postsynapses (Satoh *et al*., [@b47]).

To elucidate the causal link between the mode of action of oseltamivir and its possible behavioural side effects, we aimed to identify its molecular target(s) of this drug. Neurotransmitters such as dopamine, norepinephrine and serotonin are metabolized by MAO as shown in Supporting Information [Figure S1](#SD1){ref-type="supplementary-material"} (Youdim and Bakhle, [@b59]; Youdim *et al*., [@b60]). Because mutations in the MAO-A gene have been reported to stimulate aggressive and anxiety-like behaviours in both humans and animals (Shih *et al*., [@b48]; Caspi *et al*., [@b4]; Chen *et al*., [@b5]; Meyer *et al*., [@b37]), we hypothesized that MAO is an endogenous target of oseltamivir. Therefore, we examined the effects of OEE and OC on MAO activity *in vitro*. We also investigated whether OEE and OC injected directly into the ventricles of the brain induces spontaneous behaviour *in vivo*.

Methods
=======

Preparation of OEE and OC
-------------------------

Preparation and purification of OEE and OC (previously referred to as Ro 64-0802) are described in the Supporting Information. Both OEE and OC were dissolved in 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM CaCl~2~ and 0.01% NP-40 for use in all experiments. To permit a direct comparison with OC and to eliminate an effect of phosphate, OEE was prepared in the phosphate-free form ([Figure 1](#fig01){ref-type="fig"}A).

MAO assay
---------

MAO (EC 1.4.3.4) assays were performed using MAO-Glo™ assay reagent (Promega, Madison, WI) (Valley *et al*., [@b56]), and are described in the Supporting Information. We defined one arbitrary unit (AU) to be the amount of reaction product generated from 1 μM substrate in the assay reactions. The linearity between the AUs and substrate concentrations was reproducible. Effects of OEE on MAO V~max~ and K~m~ were determined using Michaelis--Menten and Lineweaver--Burk analyses (Dixon and Webb, [@b10]). The K~i~ values of OEE for MAO were calculated using Dixon plot and slope--replot analyses as described previously (Dixon and Webb, [@b10]; Valley *et al*., [@b56]).

*In silico* docking simulation analysis of OEE with MAO-A or MAO-B
------------------------------------------------------------------

Molecular modelling was performed using Molecular Operating Environment software (MOE; Chemical Computing Group, Quebec, Canada; Goto and Kataoka, [@b15]; Iwai *et al*., [@b22]). The X-ray crystallographic structures of MAO-A (PDB ID codes: 2Z5X and 2Z5Y) and MAO-B (2XFQ) were obtained from a protein data bank (Son *et al*., [@b49]; Bonivento *et al*., [@b2]). The details are described in the Supporting Information. To evaluate this method, we confirmed the docking of MAO-A with serotonin, a known substrate, as shown in Supporting Information [Figure S2](#SD1){ref-type="supplementary-material"}.

Pharmacological treatments
--------------------------

The details of animals used in the behavioural study are described in the Supporting Information. Mice were anaesthetized with ketamine (80 mg·kg^−1^, i.p.; Daiichi Sankyo, Tokyo, Japan) and xylazine (20 mg·kg^−1^, i.p.; Bayer, Tokyo, Japan) and mounted in a stereotaxic instrument (David Kopf Instruments, Tujunga, CA, USA). Intracerebroventricular (ICV) injections were performed as described previously (Haley and McCormick, [@b17]). Briefly, mice were implanted with a single cannula (Plastic One, Roanoke, VA, USA) placed in the right lateral ventricle. The guide cannula (23 G) (Plastic One) was inserted stereotaxically into the cerebral ventricle at positions −0.2 mm anteroposteriorly, 1.1 mm right, and −2.0 mm dorsoventrally from the bregma. The cannulas were fixed to the skull using three 7 mm stainless steel screws and dental cement. Animals were allowed to recover from surgery for at least 5 days before behavioural testing, during which time 30-G dummy cannulas were left inside the guide cannula. ICV infusions were then performed using 30-G cannulas that were cut to extend 1.0 mm beyond the end of the guide cannula. The dummy cannulas were removed and replaced with infusion cannulas that were connected to 5 μL syringes. OEE or OC (1.5 or 5 nmol per mouse) or vehicle solution (125 mM NaCl, 3.8 mM KCl, 2.0 mM CaCl~2~, 1.0 mM MgCl~2~, 1.2 mM KH~2~PO~4~, 26 mM NaHCO~3~ and 10 mM glucose) was subsequently injected through the infusion cannulas (5 μL, respectively). Dose selection was based on (i) allometric translation of the dose administered to humans -- 70 mg·day^−1^, or 1 mg·kg^−1^, which is comparable with 580 μg per mouse (40 g) or 1.8 μmol per mouse by the body surface method (Reagan-Shaw *et al*., [@b44]) and (ii) doses previously reported in the literature -- 50 mg·kg^−1^, or 6.4 μmol per mouse (assuming body weight of 40 g) administered by intraperitoneal administration (Izumi *et al*., [@b23]; [@b24]).

Behavioural analysis of the mice: automated video analysis of spontaneous physical activities in the cage
---------------------------------------------------------------------------------------------------------

Behavioural tests were conducted in mice at the age of 12--16 weeks, as previously described (Roughan *et al*., [@b45]; Kishimoto *et al*., [@b30]). Briefly, we used a digital video-based analysis system, HomeCageScan (HCS, Clever Systems, Inc., Reston, VA, USA), which automatically detected, recorded, categorized and quantified mouse behaviour. After drug treatment, each mouse was immediately placed in a clear cage (21 × 31 × 12 cm), and the spontaneous physical activities of these animals were recorded for 1 h in the home cage using a standard digital camcorder (NV-GS300, Panasonic, Osaka, Japan), which was mounted on tripods angled perpendicular to the cage to provide a side view. The camera footage was electronically stored using mAgicTV software (I-O DATA, Ishikawa, Japan). The video movie data were analysed using HCS. Spontaneous behaviours, including locomotor activity, rearing and hanging, were evaluated automatically.

Statistical analysis
--------------------

The data were analysed by Student\'s *t*-test or one-way [anova]{.smallcaps}. *Post hoc* analysis of the differences between oseltamivir-treated groups and control subjects was performed using Dunnett\'s test. Differences were considered significant at *P* \< 0.05.

Results
=======

Selective inhibition of MAO-A by OEE *in vitro*
-----------------------------------------------

To exclude any possible effects of impurities in the preparations of these compounds, OEE and OC were purified as described previously, and analysed by ^1^H-NMR (500 MHz; [Figure 1](#fig01){ref-type="fig"}A and B). All resonance spectra in ^1^H-NMR analysis were assigned to their structures of OEE and OC ([Figure 1](#fig01){ref-type="fig"}A and B), indicating that the purities of OEE and OC were \>95%.

There are two isoforms of MAO, MAO-A and MAO-B (Youdim and Bakhle, [@b59]; Youdim *et al*., [@b60]), both of which are expressed in neurons and astrocytes, although they have different functional roles. MAO-A degrades dopamine, serotonin, melatonin, norepinephrine and epinephrine, whereas MAO-B targets dopamine and phenethylamine (Supporting Information [Figure S1](#SD1){ref-type="supplementary-material"}). We first tested whether OEE or OC inhibits MAO-A using a human MAO-A assay (Valley *et al*., [@b56]) as depicted in [Figure 1](#fig01){ref-type="fig"}C. [Figure 1](#fig01){ref-type="fig"}D shows that OEE caused dose-dependent inhibition of MAO-A at concentrations of ≥10 μM (*P* \< 0.05); conversely, OC had no effect. These findings suggest that OEE, but not OC, has the capacity to exert behavioural effects, and that the ethyl ester group of OEE is important for the inhibitory effects on MAO-A ([Figure 1](#fig01){ref-type="fig"}C, D). To confirm these findings, we added OEE or OC before or after a monoamine oxidation reaction ([Figure 1](#fig01){ref-type="fig"}E). Addition of OEE prior to, but not after, monoamine oxidation decreased the product levels ([Figure 1](#fig01){ref-type="fig"}F). These data, rather than the detection steps in the assay, suggest that OEE inhibits monoamine oxidation per se.

We next tested whether OEE also inhibits MAO-B. OEE up to a concentration of 100 μM had no effect on MAO-B (150 μU) activity; rather, it caused slight stimulation ([Figure 2](#fig02){ref-type="fig"}A). OEE (100 μM) also had no effect on lower doses (40, 80 or 160 μU) of MAO-B ([Figure 2](#fig02){ref-type="fig"}B). These results indicate that OEE selectively inhibits MAO-A. Because mutations in MAO-A have been associated with some types of abnormal behaviour (Shih *et al*., [@b48]; Caspi *et al*., [@b4]; Chen *et al*., [@b5]; Meyer *et al*., [@b37]), this result is consistent with the manifestation of the stimulated behaviour in some individuals who have been treated with oseltamivir.

![Effect of OEE on MAO-B. (A) The activity of MAO-B (160 μU) was assayed in the absence or presence of OEE or OC (1, 10, 25, 50 or 100 μM). The vertical axis indicates product formation (as a percentage of the control without inhibitor). (B) OEE (100 μM) does not inhibit any activities (40, 80 or 160 μU) of MAO-B. Assays were performed in triplicate. Data are presented as mean ± SD.](bph0169-0115-f2){#fig02}

Competitive inhibition of MAO-A by OEE
--------------------------------------

To investigate the mechanism by which OEE inhibits human MAO-A, we constructed Michaelis--Menten and Lineweaver--Burk plots (Dixon and Webb, [@b10]) from the results of MAO-A assays. At a low range of substrate concentration (0--40 μM), MAO-A followed Michaelis--Menten kinetics in the absence or presence (50 or 100 μM) of OEE; OEE inhibited MAO-A at all substrate concentrations ([Figure 3](#fig03){ref-type="fig"}A). We then generated a Lineweaver--Burk plot from an MAO assay using a higher range of substrate concentrations (0--160 μM) ([Figure 3](#fig03){ref-type="fig"}B): at 0 μM OEE (control), V~max~: 8.2 (AU·h^−1^), K~m~: 18 (μM); at 50 μM OEE, V~max~: 8.2 (AU·h^−1^), K~m~: 56 (μM); at 100 μM OEE, V~max~: 10.1 (AU·h^−1^), K~m~: 111 (μM). The V~max~ values (Y-intercepts) were similar, whereas the K~m~ values (X-intercepts) markedly differed at each concentration of OEE ([Figure 3](#fig03){ref-type="fig"}B), suggesting that OEE competitively inhibits MAO-A.

![Competitive inhibition of MAO-A by OEE. (A) Dose--response curves indicating that inhibition of MAO-A by OEE follows Michaelis--Menten kinetics. MAO-A assay was performed in the absence or presence of OEE (50 or 100 μM) with MAO-A substrate (0, 2.5, 5, 10, 20 or 40 μM). (B) Lineweaver--Burk plot analysis. MAO-A assay was performed in the absence or presence of OEE (50 or 100 μM) with MAO-A substrate (0, 20, 40, 80 or 1600 μM). Assays in (A) and (B) were performed in triplicate. Data are presented as mean ± SD.](bph0169-0115-f3){#fig03}

*In silico* modelling
---------------------

To test the hypothesis that the competitive inhibition of MAO-A by OEE involves the binding of OEE to the active pocket of the enzyme, we performed *in silico* docking simulation analysis (Goto and Kataoka, [@b15]; Iwai *et al*., [@b22]) using both OEE and OC. The crystal structure of the complex of human MAO-A with harmine, a known MAO-A inhibitor, has already been reported (Son *et al*., [@b49]), providing valuable tertiary structure information for this analysis. The results showed that OEE binds deep within the narrow pocket that forms the active site; binding occurs via hydrophobic interactions between the ethyl ester group of OEE and MAO-A ([Figure 4](#fig04){ref-type="fig"}A, B). The binding site of OEE was near the flavin group of flavin adenine dinucleotide ([Figure 4](#fig04){ref-type="fig"}A, B). The binding position of OEE was found to be almost similar to that of harmine, which is also known to interact with the substrate-binding site ([Figure 4](#fig04){ref-type="fig"}A, C). This is consistent with the results shown in [Figure 3](#fig03){ref-type="fig"}B, which indicate the competitive nature of MAO-A inhibition by OEE. Because MAO catalyses its reactions using the flavin group, we conclude that OEE inhibits monoamine oxidation by disrupting its interaction with this moiety. Docking simulation of OC with human MAO-A revealed that its carboxyl group is positioned towards the entrance of the pocket and that the hydrophobic interaction via the ethyl ester group is lost ([Figure 4](#fig04){ref-type="fig"}D, E). The binding energy of OEE (−8.3 kcal·mol^−1^) was lower than that of OC (−7.1 kcal·mol^−1^), suggesting that a more stable interaction occurs between OEE and MAO-A. Taken together, these data reveal mechanistically why OEE can inhibit MAO-A, whereas OC has negligible effects.

![*In silico* docking simulation of OEE and OC with MAO-A. (A) The α-helix and β-strands of MAO-A are indicated in red and yellow respectively. OEE is shown here as a ligand. (B) Fitting of OEE to the active pocket of MAO-A. Oseltamivir is displayed in a ball-stick mode. The surface of the pocket of MAO-A is highlighted. (C) Crystal structure of the complex of MAO-A and harmine, a reversible inhibitor of MAO-A. The tertiary structure of the complex was developed using the MOE program. (D, E) *In silico* two-dimensional analysis of the interaction between OEE (D) or OC (E) forms of oseltamivir and human MAO-A. The chemical structure of OEE is shown in the centre with the key interacting amino acids depicted around it. The ethyl ester group of OEE interacts with the pocket of MAO-A. The amino acids and their numbers are indicated. The modes of the interactions are shown under each panel. (F) Comparison of the chemical structures of known MAO inhibitors and OEE. Amine groups are shown in red. Ethyl groups followed by an amine group are shown in cyan. Bulky hydrophobic groups including double bond-like phenyl groups near an ethylamine are depicted in green.](bph0169-0115-f4){#fig04}

From the viewpoint of medicinal chemistry, we compared the chemical structures of OEE and known MAO-A and MAO-B inhibitors ([Figure 4](#fig04){ref-type="fig"}F) that have been used to treat depression or Parkinson\'s disease (Youdim and Bakhle, [@b59]; Youdim *et al*., [@b60]). MAO-A inhibitors harbour an amine group (indicated in red), an ethyl group followed by an amine group (indicated in cyan), and a bulky hydrophobic group that includes a double bond-like phenyl group near ethylamine (shown in green) ([Figure 4](#fig04){ref-type="fig"}F). Oseltamivir does not have a phenyl group, but does contain a bulky hydrophobic group including a double bond ([Figure 4](#fig04){ref-type="fig"}F). Therefore, these common structures might be important for the inhibitory activity of these agents against MAO-A. Furthermore, the OEE-specific ethyl ester group forms a bulky hydrophobic group ([Figure 4](#fig04){ref-type="fig"}F), again indicating the importance of this moiety for the inhibition of MAO-A.

We also performed docking simulation analysis using MAO-B (Youdim and Bakhle, [@b59]). Tertiary structural analyses of the human MAO-A and MAO-B have revealed that although the primary structures of the two proteins are similar, human MAO-A exists as a monomer, while MAO-B adopts a dimeric conformation (Youdim and Bakhle, [@b59]; Youdim *et al*., [@b60]). The cavities of the enzyme pockets of MAO-A and MAO-B have also been reported to differ (Youdim *et al*., [@b60]). In our current *in silico* analysis, even the most stable binding result indicated that OEE might bind to the outer surface of the MAO-B protein ([Figure 5](#fig05){ref-type="fig"}A, B). The binding energy in this case was −5.0 kcal·mol^−1^ ([Figure 5](#fig05){ref-type="fig"}C), which is higher than that recorded for MAO-A (−8.3 kcal·mol^−1^; [Figure 4](#fig04){ref-type="fig"}D). This result thus provides a mechanistic underpinning to the selectivity of OEE for MAO-A.

![*In silico* docking simulation of OEE and OC with MAO-B. (A) The α-helix and β-strands of MAO-B (depicted in a ribbon structure) are shown in red and yellow, respectively. (B) Fitting of OEE to the active pocket of MAO-B. Oseltamivir is displayed in a ball and stick mode. The surface of the pocket of MAO-B is indicated. (C) Two-dimensional analysis of the interaction between OEE and MAO-B. The chemical structure of OEE is shown in the centre with the key interacting amino acids shown around it. The modes of the interactions are as shown for [Figure 4](#fig04){ref-type="fig"}D and E.](bph0169-0115-f5){#fig05}

Estimation of the K~i~ of OEE toward MAO-A
------------------------------------------

To determine the concentration of OEE that is effective in inhibiting MAO-A, we estimated its K~i~ using Dixon plot and slope--replot analyses (Dixon and Webb, [@b10]; Kamal *et al*., [@b29]). Analysis of the Dixon plot of a MAO-A assay using 20, 40, 80 or 160 μM of substrate, and 0, 50 or 100 μM of OEE revealed an estimated K~i~ value of 28 μM ([Figure 6](#fig06){ref-type="fig"}A); slope--replot analysis revealed an estimated K~i~ value of 25 μM ([Figure 6](#fig06){ref-type="fig"}B). Because the K~m~ values of serotonin and dopamine, determined using the same methods that we used here, were reported to be 45 and 21 μM, respectively (Supporting Information [Table S1](#SD1){ref-type="supplementary-material"}; Valley *et al*., [@b56]), the K~i~ value of OEE can be considered effective.

![Estimation of the K~i~ of OEE against MAO-A. (A) Dixon plot analysis. MAO-A assay was performed in the absence or presence of OEE (50 or 100 μM) with MAO substrate (0, 20, 40, 80 or 160 μM). At the intersection point, the concentration of substrate indicates the −K~i~ value, estimated at 25 μM in this analysis. (B) Slope-replot analysis. In this plot, the X-intercept indicates the −K~i~ value, estimated at 28 μM as shown.](bph0169-0115-f6){#fig06}

Stimulation of mouse behaviour by OEE, but not OC
-------------------------------------------------

To investigate whether OEE specifically induces spontaneous behaviour *in vivo*, we performed *in vivo* behaviour analysis on mice administered OEE or OC by ICV injection using a computer-based behavioural analysis system (Roughan *et al*., [@b45]; HCS, Supporting Information [Figure S3](#SD1){ref-type="supplementary-material"}). Typical examples of computer-based analysis of mouse behaviours are shown in Supporting Information movies. OEE, but not OC, induced increased 'rearing', 'turning', 'walking', 'jumping' and 'sniffing' by the animals ([Figure 7](#fig07){ref-type="fig"} and Supporting Information Movies). OEE also increased 'distances travelled' by almost twofold of those in control mice, and significantly decreased 'twitching' and 'inactive behaviours' such as pausing, remaining low, sleeping, and the lengths of time in a stationary position ([Figure 7](#fig07){ref-type="fig"}). In contrast, 'grooming', 'hanging' and 'stretching' were not affected ([Figure 7](#fig07){ref-type="fig"}). Increases in 'walking' and 'distance travelled', basal barometers, were dose-dependent, while 'rearing', 'jumping' and 'sniffing' increased only at the 5 nmol dose. This may be due to differences in the sensitivities to OEE. In contrast, the 'inactive behaviour' parameter showed a tendency towards a dose-dependent decrease. This is the first demonstration of stimulation of mouse behavioural activities by OEE. These effects are consistent with our *in vitro* biochemical and *in silico* docking results.

![Behavioural analysis of OEE-injected mice *in vivo*. Behaviours of mice injected with vehicle (control, *n* = 9), 1.5 or 5 nmol of OEE (*n* = 9 or 11), or 5 nmol of OC (*n* = 9) were recorded and analysed using the HomeCageScan system. The vertical axes indicate the times of behaviours per hour (s·h^−1^), the distance travelled (m·h^−1^), or the period of inactivity (s·h^−1^). ^\#^*P* \< 0.05 (vs. the control group) by Student\'s *t*-test; \**P* \< 0.05, and \*\**P* \< 0.01 (vs. the corresponding control group) by *post hoc* Dunnett\'s test. Data are represented as mean ± SEM.](bph0169-0115-f7){#fig07}

Discussion
==========

A working model
---------------

This is the first report to reveal the molecular target of oseltamivir, and thereby the first to provide an explanation for its behavioural effects. On the basis of our current data and previously reported results, we have devised a working model illustrated schematically in [Figure 8](#fig08){ref-type="fig"} to explain the rare occurrence of stimulated behaviour in young people receiving oseltamivir. In almost all individuals, OEE was converted to OC by carboxylesterase 1A1 (HCE1) in the liver (Zhu and Markowitz, [@b61]; Zhu *et al*., [@b62]; Abdel-Rahman *et al*., [@b1]; Tarkiainen *et al*., [@b52]; [Figures 1](#fig01){ref-type="fig"}C and [8](#fig08){ref-type="fig"}), with no impact on MAO-A activity ([Figure 1](#fig01){ref-type="fig"}D) and thus no adverse effects ([Figure 8](#fig08){ref-type="fig"}). However, if this conversion does not occur or is inefficient, as has been shown in juvenile rat livers (Ose *et al*., [@b41]), the concentration of OEE will increase in the bloodstream ([Figure 8](#fig08){ref-type="fig"}). Zhu *et al*. ([@b62]) reported that the expression and the activity of human carboxylesterase 1 increase in an age-dependent manner. Impairment of the bioactivation of OEE by a carboxylesterase 1 polymorphism and side effects of OEE in a patient with liver cirrhosis have also been reported (Kaji *et al*., [@b28]; Zhu and Markowitz, [@b61]; Tarkiainen *et al*., [@b52]). Moreover, oseltamivir has been reported to affect liver function (El-Sayed and Al-Kahtani, [@b12]). Together, these results support our model by providing a possible explanation for the rare occurrence of adverse effects.

![Proposed model for the effects of OEE on MAO-A and the resulting behavioural impact in humans. P-gp: P-glycoprotein.](bph0169-0115-f8){#fig08}

Role of the blood--brain barrier in our working model
-----------------------------------------------------

Another consideration from our working model is the nature of the transfer of OEE into the brain as a function of age or disease state. L\'Huillier *et al*. ([@b32]) have reported that a human polymorphism in *ABCB1*, the gene that encodes P-glycoprotein at the blood--brain barrier, is associated with oseltamivir-related neuropsychiatrical adverse effects in children and young adults, indicating that the blood--brain barrier is important for the effect in these age groups ([Figure 8](#fig08){ref-type="fig"}). Other studies have shown that OEE accumulates in the juvenile rat brain at a higher level than OC does, because of the difference in the preference for P-glycoprotein (Ose *et al*., [@b41]; [@b42]; [Figure 8](#fig08){ref-type="fig"}). Moreover, Freichel *et al*. ([@b13]) reported that the concentration of OEE in the brain is higher than that of OC, although these measurements in the plasma are controversial. The finding that the brain concentrations of OEE and OC increased in the presence of inflammation (Oshima *et al*., [@b43]), which can be induced by the influenza virus, is consistent with the observation that severe influenza causes hyperpermeability in the brain (Wang *et al*., [@b57]). Co-morbidity with influenza encephalopathy has also been described (UCM303007.pdf in FDA web site). Thus, if the blood--brain barrier is perturbed by influenza encephalopathy, OEE could more effectively distribute the brain ([Figure 8](#fig08){ref-type="fig"}).

Our working model is thus consistent with the current body of evidence and provides a plausible explanation as to why OEE has adverse effects in only some instances and only in children and adolescents. Moreover, the claims that oseltamivir is safe overall and that it has neuropsychiatrical activity in rare cases are not contradicted in our model. It is likely that most people can continue to safely use oseltamivir, but awareness of the possible, albeit rare, side effects of this drug in individuals who may have a metabolic or blood--brain barrier condition would be prudent.

Higher incidence of OEE behavioural side effects in Japanese
------------------------------------------------------------

Sabol *et al*. ([@b46]) reported that 33% of white/non-Hispanic individuals and 61% of Asians/Pacific islanders show low activity of the MAO-A promoter variant. This suggests there are ethnic differences in the sensitivity to MAO inhibitors, which may explain differences in the incidence of adverse effects of oseltamivir in different races. Furthermore, synergistic effects of oseltamivir with alcohol on neuronal function have been reported (Izumi *et al*., [@b23]). Metabolites of monoamine generated by the activity of MAO are further metabolized by aldehyde dehydrogenase (ALDH; Supporting Information [Figure S1](#SD1){ref-type="supplementary-material"}), which also degrades alcohol. Our current results provide an explanation for the molecular mechanism underlying this synergy. Approximately, 40% of the Japanese population lacks or is heterozygous for ALDH2, which is expressed in the brain and other tissues (Supporting Information [Figure S1](#SD1){ref-type="supplementary-material"}) (Crabb *et al*., [@b7]). The inhibition of MAO-A by OEE coupled with an ALDH2 deficiency might induce synergistic effects on this pathway in Japanese patients (Supporting Information [Figure S1](#SD1){ref-type="supplementary-material"}). Because many teenagers do not consume alcohol, it is also possible that their ALDH is not induced *in vivo* and is therefore maintained at lower levels than in adults. Together, these may explain why the side effects of oseltamivir are observed mainly in younger Japanese patients (Supporting Information [Figure S1](#SD1){ref-type="supplementary-material"}).

Concentration aspects
---------------------

Recently, Freichel *et al*. ([@b13]) reported that the average concentrations of oseltamivir in cerebrospinal fluid and in the brains of healthy rats reached 1120 ng·mL^−1^ (3.6 μM) and 2310 ng·g^−1^ (7.4 μM), respectively. ^11^C-labelled oseltamivir analyses showed that oseltamivir is strictly localized in the infant brain; high levels were especially noted in the pineal body, (Hatori *et al*., [@b20]; Takashima *et al*., [@b51]), which produces melatonin, a substrate of MAO-A. Thus, accumulation of oseltamivir such that it approaches the Ki concentration of MAO-A may elicit more potent effects on MAO-A in this region. Furthermore, Toovey *et al*. have previously simulated the inhibition of the conversion of OEE to OC and found that it leads to a 14-fold higher concentration of OEE (Toovey *et al*., [@b53]).

Behavioural analysis
--------------------

The stimulated behaviours in mice are consistent with the neuropsychiatric adverse effects in humans following oseltamivir administration. The increased distance travelled by mice because of OEE in the present study seems to mimic the stimulation of running in humans. Furthermore, in clinical cases, mood disorders associated with oseltamivir have been reported (UCM303006.pdf in FDA website), further suggesting an association, since mood is related to the actions of MAO.

Subcutaneous (s.c.) administration of 1--4 mg·kg^−1^ of amphetamine -- a known inhibitor of MAO-A -- stimulates spontaneous behaviours in mice in a dose-dependent manner (Hirabayashi *et al*., [@b21]). Another study has demonstrated that amphetamine (2.5 mg·kg^−1^, s.c.) induces enhanced locomotor activity in mice, whereas mice administered doses of amphetamines greater than 5 mg·kg^−1^ exhibit significant stereotypy (McNamara *et al*., [@b35]). Although the methods of administration and the dosages were unrelated, these findings are consistent with those reported in the present study.

Additional targets
------------------

Moclobemide is a reversible MAO-A inhibitor showing antidepressant activity. Moclobemide has almost no effect on spontaneous behaviour in mice, although a slight impairment in motor performance is seen at higher doses only (Burkard *et al*., [@b3]). Hence, we contend that the mechanism of action of oseltamivir might not be fully equivalent to that of MAO-A inhibitors such as moclobemide. Oseltamivir has been reported to induce depressive episodes in humans (Chung and Joung, [@b6]). Although this seems contrary to its MAO-A inhibition profile, because brain functions are regulated by a fine balance of monoamines, we believe that this is not so. For example, the role of the MAO-A gene in bipolar affective disorder has been reported (Furlong *et al*., [@b14]). However, this suggests that there may be additional targets that influence behaviour in humans, although Satoh *et al*. ([@b47]) showed that neither Tamiflu nor GS4071 (OC) influence the re-uptake or release of monoamines in postsynapses. As indicated by our current findings, there are structural similarities among oseltamivir and monoamines ([Figure 2](#fig02){ref-type="fig"}H). Hence, OEE may possibly block or stimulate the other monoamine machineries.

Conclusions
-----------

We conclude that OEE, but not OC is responsible for the occasionally observed behavioural side effects of oseltamivir and that MAO-A is one of the important targets. The finding that OC does not inhibit human endogenous neuraminidases (Hata *et al*., [@b18]) is also consistent with our conclusion that OEE is the cause of rare adverse behavioural effects. On the basis of our findings, we do not advocate that oseltamivir treatment be discontinued in young people, but we do suggest that guidelines be developed for safer use of this drug in this particular age group. It should be possible, for example, to develop OEE that does not inhibit MAO-A.
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**Figure S1** Degradation of neurotransmitters such as dopamine and serotonin by MAO-A and MAO-B, and by aldehyde dehydrogenase. MAOs deaminate monoamines into their aldehyde forms, which are subsequently converted into a carboxylate form by aldehyde dehydrogenase. Both the A and B forms of MAO deaminate dopamine to produce 3,4-dihydroxyphenylacetaldehyde (DOPAldehyde). This compound is subsequently converted into 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase.

**Figure S2** *In silico* docking simulation of serotonin with MAO-A. (A) To validate the *in silico* docking simulation, we performed this analysis of MAO-A using serotonin, a known substrate. The results showed that serotonin was fitted into the active pocket of MAO-A. The α-helix and β-strands are shown in red and yellow, respectively. Serotonin is shown here as a ligand and is displayed in a sphere mode. (B) *In silico* two-dimensional analysis of the interaction between serotonin and human MAO-A. The chemical structure of serotonin is shown in the centre with the key interacting amino acids depicted around it. The amino acids and their numbers are indicated. The modes of the interactions are shown.

**Figure S3** Schema of injections into the mouse brain and subsequent behavioural analysis shown in [Figure 7](#fig07){ref-type="fig"}.

**Table S1** Comparison of the Ki & Km values of OEE and other inhibitors and native substrates of MAO-A.

**Supporting Information Movies** Enhanced spontaneous physical activities (SPA) in mice injected with OEE. These 1-minute-movies show typical behavioural activities in mice from 5 minutes after the intraventricular injection of OEE. These mouse behaviours were recorded by video and analyzed using the HomeCageScan system. Stimulated behaviours were noticeable in OEE-injected mice (OEE1.mov, OEE2.mov, and OEE3.mov). The walk distances in the injected animals were as follows: 2.60, 2.52, and 2.21 m for OEE; 0.64 m for OC (OC.mov); and 0.57 m for the controls (control.mov). The yellow, pink, and cyan lines indicate the edges of the cage. The green line indicates the feeding basket. The very short red line in the centre denotes the faucet of the drinking bottle. The moving grey line shows the mouse body.

**Supplementary Information** Methods, Discussion and References.
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